Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Drugs 2021, Part 2.

Nursing·2021
Same author

New Drugs 2021, Part 1.

Nursing·2021
Same author

New Drug Update 2020.

The Senior care pharmacist·2021
Same author

New drugs 2020, part 3.

Nursing·2020
Same author

Is the Quality of Generic Drugs Cause for Concern?

Journal of managed care & specialty pharmacy·2020
Same author

New Drugs 2020, part 2.

Nursing·2020
Same journal

Bridging disciplines through Alzheimer care: A faculty-guided summer interprofessional education experience for prelicensure nursing students.

Nursing·2026
Same journal

Improving outcomes by empowering nurses to lead change in an acute stroke unit.

Nursing·2026
Same journal

Q&A with Ken Wofford, PhD, CRNA, CHSE, FAWM, DiMM.

Nursing·2026
Same journal

Oral anticoagulant medications.

Nursing·2026
Same journal

Signs, signs, everywhere a sign!

Nursing·2026
Same journal

How does postural orthostatic tachycardia syndrome (POTS) affect pediatric patients?

Nursing·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

New drugs08, part 2.

Daniel A Hussar1

  • 1Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA, USA.

Nursing
|June 27, 2008
PubMed
Summary
This summary is machine-generated.

This article reviews eight novel medications, including doripenem for infections, maraviroc for HIV, and ixabepilone for breast cancer. Information is for adults, with pregnancy and breastfeeding safety details requiring consultation.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Experiment Videos

Last Updated: Jul 4, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Area of Science:

  • Pharmacology
  • Oncology
  • Infectious Diseases

Background:

  • Emerging pharmaceutical developments offer new therapeutic options.
  • Addressing unmet needs in complex infections and advanced cancers is crucial.
  • Antiretroviral therapy continues to evolve for managing HIV.

Purpose of the Study:

  • To introduce and summarize key information on eight newly approved drugs.
  • To provide concise details on indications, target patient populations, and safety considerations.
  • To highlight advancements in treating intra-abdominal infections, urinary tract infections, HIV, and metastatic breast cancer.

Main Methods:

  • Review of drug approval information and package inserts.
  • Summarization of clinical applications and safety profiles for each new drug.
  • Focus on adult indications, with notes on pregnancy and breastfeeding precautions.

Main Results:

  • Doripenem: A carbapenem antibiotic approved for complicated intra-abdominal and urinary tract infections.
  • Maraviroc: A CCR5 antagonist indicated for treatment-experienced adult patients with CCR5-tropic HIV-1 infection.
  • Ixabepilone: An epoxide analog of epothilone approved for metastatic or locally advanced breast cancer.

Conclusions:

  • These new drugs represent significant therapeutic advancements in their respective fields.
  • Healthcare providers should consult detailed prescribing information for comprehensive safety and efficacy data.
  • Patient-specific factors, including pregnancy and breastfeeding status, require careful consideration.